Corvus Pharmaceuticals, Inc.
CRVS
$6.94
-$0.31-4.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 24.86% | 19.80% | 19.99% | 15.90% | 3.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.04% | 35.35% | 18.08% | 7.99% | -22.04% |
| Operating Income | -52.04% | -35.35% | -18.08% | -7.99% | 22.04% |
| Income Before Tax | -99.57% | -66.55% | -130.47% | -88.24% | 42.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -99.57% | -66.55% | -130.47% | -88.24% | 42.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -99.57% | -66.55% | -130.47% | -88.24% | 42.04% |
| EBIT | -52.04% | -35.35% | -18.08% | -7.99% | 22.04% |
| EBITDA | -52.31% | -35.67% | -18.49% | -8.60% | 21.64% |
| EPS Basic | -50.77% | -25.32% | -71.53% | -44.87% | 46.63% |
| Normalized Basic EPS | -50.77% | -25.27% | -71.51% | -44.73% | 46.66% |
| EPS Diluted | -125.78% | -90.97% | -72.19% | -44.84% | 46.36% |
| Normalized Diluted EPS | -52.67% | -26.93% | -71.51% | -44.73% | 46.66% |
| Average Basic Shares Outstanding | 37.82% | 37.18% | 26.94% | 18.41% | 10.47% |
| Average Diluted Shares Outstanding | 39.28% | 38.74% | 26.94% | 18.41% | 10.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |